NovoCure Limited (NASDAQ: NVCR) stock closed at 94.22 per share at the end of the most recent trading day (a -0.91% change compared to the prior day closing price) with a volume of 740.17K shares and market capitalization of 9.89B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1023 people. NovoCure Limited CEO is Asaf Danziger.

The one-year performance of NovoCure Limited stock is 37.18%, while year-to-date (YTD) performance is 28.45%. NVCR stock has a five-year performance of 342.35%. Its 52-week range is between 56.39 and 120.03, which gives NVCR stock a 52-week price range ratio of 59.44%

NovoCure Limited currently has a PE ratio of -141.60, a price-to-book (PB) ratio of 25.69, a price-to-sale (PS) ratio of 23.39, a price to cashflow ratio of 232.80, a PEG ratio of 2.32, a ROA of -7.69%, a ROC of -8.12% and a ROE of -20.54%. The company’s profit margin is -13.49%, its EBITDA margin is -11.70%, and its revenue ttm is $409.41 Million , which makes it $3.90 revenue per share.

Of the last four earnings reports from NovoCure Limited, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. NovoCure Limited’s next earnings report date is 23rd Feb 2023.

The consensus rating of Wall Street analysts for NovoCure Limited is Hold (2.75), with a target price of $107.43, which is +14.02% compared to the current price. The earnings rating for NovoCure Limited stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

NovoCure Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

NovoCure Limited has a Buy technical analysis rating based on Technical Indicators (ADX : 19.16, ATR14 : 5.36, CCI20 : 23.39, Chaikin Money Flow : -0.09, MACD : 2.70, Money Flow Index : 46.78, ROC : 1.50, RSI : 57.75, STOCH (14,3) : 84.56, STOCH RSI : 0.76, UO : 58.87, Williams %R : -15.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of NovoCure Limited in the last 12-months were: Asaf Danziger (Sold 0 shares of value $-1 627 125 ), Asaf Danziger (Sold 212 500 shares of value $23 106 230 ), Ashley Cordova (Sold 0 shares of value $0 ), Ashley Cordova (Sold 3 349 shares of value $247 898 ), Ely Benaim (Sold 12 914 shares of value $901 551 ), Frank Leonard (Sold 0 shares of value $-468 670 ), Frank Leonard (Sold 138 762 shares of value $12 188 798 ), Jeryl L. Hilleman (Sold 407 shares of value $28 331 ), Pritesh Shah (Sold 13 974 shares of value $1 007 237 ), Todd Christopher Longsworth (Sold 5 406 shares of value $384 378 ), Uri Weinberg (Sold 0 shares of value $-91 540 ), Uri Weinberg (Sold 8 143 shares of value $945 756 ), Wilhelmus C. M. Groenhuysen (Sold 7 089 shares of value $506 095 ), William F. Doyle (Sold 3 222 shares of value $225 493 ), William Patrick Burke (Sold 3 122 shares of value $227 084 )